New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral ResearchGlobeNewsWire • 03/08/23
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 02/28/23
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023GlobeNewsWire • 02/23/23
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023GlobeNewsWire • 02/21/23
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile at Conference on Retroviruses and Opportunistic InfectionsGlobeNewsWire • 02/15/23
Atea Pharmaceuticals to Present at the SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/07/23
Atea Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/23
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19GlobeNewsWire • 11/29/22
Atea Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/22/22
Atea Pharmaceuticals, Inc. (AVIR) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 11/10/22
After Plunging 10.6% in 4 Weeks, Here's Why the Trend Might Reverse for Atea Pharmaceuticals, Inc. (AVIR)Zacks Investment Research • 11/10/22
Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q3 2022 -Results Earnings Call TranscriptSeeking Alpha • 11/08/22
Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/07/22
Why Atea Pharmaceuticals (AVIR) Might Surprise This Earnings SeasonZacks Investment Research • 11/04/22
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022GlobeNewsWire • 10/31/22
Atea to Advance Global Phase 3 Registrational Study of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19GlobeNewsWire • 09/13/22
Atea Pharmaceuticals, Inc. (AVIR) CEO Jean-Pierre Sommadossi on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/08/22
Atea Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call on August 8, 2022GlobeNewsWire • 08/01/22
Atea Pharmaceuticals, Inc. (AVIR) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 07/13/22
Atea Pharmaceuticals Participates in the William Blair Biotech Focus ConferenceGlobeNewsWire • 07/11/22